



## The Sphingolipid Pathway in Cancer

Guest Editors:

**Prof. Dr. Stuart M. Pitson**

Centre for Cancer Biology,  
University of South Australia and  
SA Pathology, Adelaide, SA 5000,  
Australia

**Prof. Nigel Pyne**

Strathclyde Institute of Pharmacy  
and Biomedical Sciences,  
University of Strathclyde, 161  
Cathedral St, Glasgow G40RE,  
Scotland, UK

**Dr. Melissa Pitman**

Centre for Cancer Biology,  
University of South Australia and  
SA Pathology, Adelaide SA 5001,  
Australia

Deadline for manuscript  
submissions:

**closed (30 November 2019)**

### Message from the Guest Editors

Dear Colleagues,

Sphingolipids have long been known to play critical roles in the properties of cellular membranes. Research over the last three decades, however, has shown a number of sphingolipids to also be important signaling molecules that regulate a wide array of biological processes. In particular, sphingolipids, including but not limited to the ceramides and sphingosine 1-phosphate, have been shown to be important regulators of cell fate, influencing cell survival and proliferation, as well as cell differentiation. For this reason, the sphingolipid pathway has garnered significant interest as a target for anticancer therapies.

This Special Issue of *Cancers* seeks reviews and original papers that examine the roles of the sphingolipid pathway and its various individual components in cancers. The objective is to highlight the current understanding of the regulation of sphingolipid metabolism and signaling, its impact on cancer initiation, progression and responses to therapy, including chemoresistance, and how this information may be exploited for therapeutic benefit.

Prof. Stuart Pitson

Prof. Nigel Pyne

Dr. Melissa Pitman

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)